Effect of Thrombolysis on 30-day Mortality in Intermediate High Risk Pulmonary Patients With Low Bleeding Risk

NCT07374978 · clinicaltrials.gov ↗

NA

Phase

COMPLETED

Status

100

Enrollment

OTHER

Sponsor class

Conditions

Pulmonary Embolism Subacute Massive
Thrombolytic Therapy

Interventions

DRUG: Thrombolytic therapy for the study group in the form of streptokinase or recombinant tissue plasminogen activator
DRUG: Unfractionated Heparin IV

Sponsor

Ain Shams University